Asthma and COPD Drugs Market by Medication Class (Combination Drugs, Inhaled Corticosteroids (ICS), Diseases (Asthma and COPD) and Short Acting Beta Agonists (SABA), Long Acting Beta Agonists (LABA), Leukotriene Antagonists (LTA), Anticholinergics, and Others.) - Partner & Customer Ecosystem (Product Services, Proposition & Key Features) Competitive Index & Regional Footprints by MarketDigits - Forecast 2024-2032

Industry : Healthcare | Pages : 179 Pages | Upcoming : Jun 2024

         
     

The market size of global asthma and COPD drugs was $32,988.7 million in 2022, and it is expected to reach $52,049.54 million by 2030, with a compound annual growth rate (CAGR) of 4.64% from 2023 to 2030. Asthma is a chronic inflammatory lung disorder characterized by recurrent episodes of wheezing, breathlessness, chest tightness, and coughing, primarily triggered by allergens and irritants. It is a reversible condition compared to other obstructive lung diseases. On the other hand, chronic obstructive pulmonary disease (COPD) is characterized by irreversible airflow limitation, including emphysema and chronic bronchitis. COPD is primarily caused by tobacco smoking, but passive smoking, occupational exposure, and air pollution also contribute to its development.

Diagnosis of asthma and COPD involves physical examinations and various tests such as X-rays, sputum eosinophils, and nitric oxide tests. Treatment options for both conditions include inhaled corticosteroids, leukotriene modifiers, and theophylline. Acute respiratory attacks can be managed with short-acting beta agonists and anticholinergic drugs.

The growth of the global market for asthma and COPD drugs is primarily driven by the increasing prevalence of these conditions. According to the World Health Organization (WHO), asthma affected approximately 262 million people and caused 461,000 deaths in 2019. Similarly, the American Lung Organization reported that in 2022, 99 million adults in the United States had chronic bronchitis, and 2 million adults had emphysema. These rising numbers of asthma and COPD patients contribute to the market's growth.

Furthermore, the market growth of global asthma and chronic obstructive pulmonary disease (COPD) drugs is expected to be boosted by advancements in respiratory diseases therapy and the introduction of new products. For example, in December 2022, AstraZeneca, a prominent pharmaceutical manufacturer, obtained EU Approval for 'Trixeo Aerosphere' as a maintenance treatment for COPD. However, the high cost of asthma treatment poses a hindrance to market growth throughout the forecast period.

Global Asthma And Copd Drugs Market Segmentation

By DISEASES

  • Asthma
  • COPD

By MEDICATION CLASS

  • Combination Drugs
  • Short Acting Beta Agonists (SABA)
  • Long Acting Beta Agonists (LABA)
  • Leukotriene Antagonists (LTA)
  • Anticholinergics
  • Others

By Region

  • North America  (U.S, Canada, Mexico)
  • Europe  (Germany, France, UK, Italy, Spain, Rest of Europe)
  • Asia Pacific  (Japan, China, Australia, India, South Korea, Rest of Asia Pacific)
  • LAMEA  (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)

The market for Asthma and COPD drugs is divided into different segments based on the disease, medication class, and region. In terms of disease, the market is categorized into asthma and COPD. The medication class segment includes combination drugs, inhaled corticosteroids (ICS), short-acting beta agonists (SABA), long-acting beta agonists (LABA), leukotriene antagonists (LTA), anticholinergics, and others.

Regionally, the market for Asthma and COPD drugs is analyzed across North America (including the U.S., Canada, and Mexico), Europe (including Germany, France, the UK, Italy, Spain, and the rest of Europe), Asia-Pacific (including Japan, China, Australia, India, South Korea, and the rest of Asia-Pacific), and LAMEA (including Brazil, South Arabia, South Africa, and the rest of LAMEA).

In terms of disease, the asthma segment dominated the market in 2022, and this trend is expected to continue due to the increasing number of asthma patients. However, the COPD segment is projected to witness significant growth during the forecast period, driven by advancements in COPD therapy.

Regarding medication class, the combination drugs segment was the major contributor in 2022 and is expected to maintain its leading position during the forecast period, mainly due to the reliability of combination therapy. However, the inhaled corticosteroids segment is expected to experience substantial growth in the coming years, attributed to advancements in therapy.

In terms of region, North America held the largest share in the Asthma and COPD drugs market in 2022 and is expected to dominate the global market throughout the forecast period. This is due to the high prevalence of asthma, the presence of key manufacturing players, tobacco smoking habits, and a well-established infrastructure in the region. However, Asia-Pacific is anticipated to register the highest compound annual growth rate (CAGR) of 5.81% from 2023 to 2030, driven by the increasing number of hospitals and a large population.

Key Benefits For Stakeholders

  • This report presents a detailed analysis of the global Asthma and COPD Drugs Market, including its size, current trends, and future projections, aiming to identify lucrative investment opportunities.
  • The analysis covers the period from 2023 to 2030, providing valuable insights for stakeholders to make informed decisions and take advantage of the potential opportunities in the market.
  • Furthermore, a comprehensive examination of regional markets helps to understand the specific dynamics and opportunities in each region, supporting strategic business planning.
  • The report also includes an in-depth analysis of key players' profiles and growth strategies, offering a clear understanding of the competitive landscape and growth prospects in the global Asthma and COPD Drugs Market.

TOC

Table and Figures

Methodology:

At MarketDigits, we take immense pride in our 360° Research Methodology, which serves as the cornerstone of our research process. It represents a rigorous and comprehensive approach that goes beyond traditional methods to provide a holistic understanding of industry dynamics.

This methodology is built upon the integration of all seven research methodologies developed by MarketDigits, a renowned global research and consulting firm. By leveraging the collective strength of these methodologies, we are able to deliver a 360° view of the challenges, trends, and issues impacting your industry.

The first step of our 360° Research Methodology™ involves conducting extensive primary research, which involves gathering first-hand information through interviews, surveys, and interactions with industry experts, key stakeholders, and market participants. This approach enables us to gather valuable insights and perspectives directly from the source.

Secondary research is another crucial component of our methodology. It involves a deep dive into various data sources, including industry reports, market databases, scholarly articles, and regulatory documents. This helps us gather a wide range of information, validate findings, and provide a comprehensive understanding of the industry landscape.

Furthermore, our methodology incorporates technology-based research techniques, such as data mining, text analytics, and predictive modelling, to uncover hidden patterns, correlations, and trends within the data. This data-driven approach enhances the accuracy and reliability of our analysis, enabling us to make informed and actionable recommendations.

In addition, our analysts bring their industry expertise and domain knowledge to bear on the research process. Their deep understanding of market dynamics, emerging trends, and future prospects allows for insightful interpretation of the data and identification of strategic opportunities.

To ensure the highest level of quality and reliability, our research process undergoes rigorous validation and verification. This includes cross-referencing and triangulation of data from multiple sources, as well as peer reviews and expert consultations.

The result of our 360° Research Methodology is a comprehensive and robust research report that empowers you to make well-informed business decisions. It provides a panoramic view of the industry landscape, helping you navigate challenges, seize opportunities, and stay ahead of the competition.

In summary, our 360° Research Methodology is designed to provide you with a deep understanding of your industry by integrating various research techniques, industry expertise, and data-driven analysis. It ensures that every business decision you make is based on a well-triangulated and comprehensive research experience.

Customize your Report
• Tailored advice to Drive your Performance
• Product Planning Strategy
• New Product Stratergy
• Expanded Research Scope
• Comprehensive Research
• Strategic Consulting
• Provocative and pragmatic
• Accelerate Revenue & Growth
• Evaluate the competitive landscape
• Optimize your partner network
• Analyzing industries
• Mapping trends
• Strategizing growth
• Implementing plans
A comprehensive cogent custom study with Analyzing Industries, Mapping Trends, Straterging growth & Implementing Plans. An in-depth and breadth of composite research, which gives complete support of the generation and evaluation of growth opportunities, and best practices recognition to help increase the revenue. Request a Custom Research below.
Request Customization

Covered Key Topics

Growth Opportunities

Market Growth Drivers

Leading Market Players

Company Market Share

Market Size and Growth Rate

Market Trend and Technological

Research Assistance

We will be happy to help you find what you need. Please call us or write to us:

+1 510-730-3200 (USA Number)

Email: sales@marketdigits.com